Merck falls short in PhIII Covid-19 prophylaxis trial, joining Pfizer
Merck took another swing at bat to bolster its case for its Covid-19 antiviral — and that swing turned into yet another miss.
The pharma giant said Tuesday morning that its antiviral molnupiravir, branded as Lagevrio, failed to show “a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19” in a Phase III trial.
The study enrolled more than 1,500 participants — all who lived with someone who was newly diagnosed with Covid-19. That household member was also showing at least one symptom or sign of the disease, and had not had said symptoms for more than five days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.